- ￥5000
- 齐源
- 127643
- 国产/进口
- 2025年07月12日
- FC
- 大鼠
- 小鼠
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
Ly-6G
- 级别：
Ly-6G Antibody
- 目录编号：
Ly-6G Antibody
- 克隆性：
单克隆
- 抗原来源：
大鼠
- 保质期：
Ly-6G Antibody
- 抗体英文名：
Brilliant Violet 711™ anti-mouse Ly-6G Antibody
- 抗体名：
Ly-6G Antibody
- 标记物：
Ly-6G Antibody
- 宿主：
大鼠
- 适应物种：
小鼠
- 免疫原：
Ly-6G Antibody
- 亚型：
Ly-6G Antibody
- 形态：
Ly-6G Antibody
- 应用范围：
FC
- 保存条件：
2-8℃
- 浓度：
0.2 mg/ml
- 规格：
50 µg
Brilliant Violet 711™ anti-mouse Ly-6G Antibody详细如下：
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation ：The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™under optimal conditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm isrecommended for detection, although filter optimization may be required depending on otherfluorophores used. Be sure to verify that your cytometer configuration and software setupare appropriate for detecting this channel. Refer to your instrument manual or manufacturerfor support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.
Excitation Laser ：Violet Laser (405 nm)
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation ：The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™under optimal conditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm isrecommended for detection, although filter optimization may be required depending on otherfluorophores used. Be sure to verify that your cytometer configuration and software setupare appropriate for detecting this channel. Refer to your instrument manual or manufacturerfor support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.
Excitation Laser ：Violet Laser (405 nm)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
2. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
3. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
4. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
5. Seydoux E, et al. 2021. Cell Reports. 35(5):109084. PubMed
6. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
7. Clark JT, et al. 2021. eLife. 10:00. PubMed
8. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
9. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
10. Voeller J, et al. 2019. J Immunother Cancer. 0.530555556. PubMed
11. Baker GJ, et al. 2020. Cell Syst. 0.647222222. PubMed
12. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
2. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
3. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
4. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
5. Seydoux E, et al. 2021. Cell Reports. 35(5):109084. PubMed
6. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
7. Clark JT, et al. 2021. eLife. 10:00. PubMed
8. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
9. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
10. Voeller J, et al. 2019. J Immunother Cancer. 0.530555556. PubMed
11. Baker GJ, et al. 2020. Cell Syst. 0.647222222. PubMed
12. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
文献支持
Brilliant Violet 711™ 抗小鼠 Ly-6G 抗体
￥5000
